Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis

NCT02267135 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

102

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Scalp Psoriasis

Interventions

BIOLOGICAL: Secukinumab 300 mg
BIOLOGICAL: Placebo

Sponsor

Novartis Pharmaceuticals